The complaint filed by the Law Offices of Frank R. Cruz alleges that Phreesia executives artificially bolstered investor confidence by masking risks associated with the company’s Network Solutions segment. While the firm publicly asserted that its pharmaceutical marketing commitments served as a reliable engine for long-term expansion, the lawsuit contends these projections were inherently uncertain and threatened the company’s fiscal year 2027 revenue targets.

Shareholders who purchased shares during the specified period are not required to take immediate action to remain part of the class, as they may either retain independent counsel or wait for further developments in the case. Those interested in assuming a leadership role in the litigation must file their applications by the July 13 deadline. For inquiries regarding legal rights or participation, the Law Offices of Frank R. Cruz can be reached at 310-914-5007 or via email.